Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data.
about
New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncologyExpanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathwaysSynergistic interactions between HDAC and sirtuin inhibitors in human leukemia cellsStructural basis for resistance to diverse classes of NAMPT inhibitorsIDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer CellsNAD+ and SIRT3 control microtubule dynamics and reduce susceptibility to antimicrotubule agents.Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid.NADH autofluorescence, a new metabolic biomarker for cancer stem cells: Identification of Vitamin C and CAPE as natural products targeting "stemness".The complex landscape of pancreatic cancer metabolismDiscovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferaseDiscovery of Novel Inhibitors and Fluorescent Probe Targeting NAMPT.Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarctionCD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cellsDependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase.PBEF/NAMPT/visfatin: a promising drug target for treating rheumatoid arthritis?Radionuclide therapy via SSTR: future aspects from experimental animal studies.EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia.Physiological and pathophysiological roles of NAMPT and NAD metabolism.Crystal structure-based comparison of two NAMPT inhibitors.Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma.Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines.Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is a tumoural cytokine released from melanoma.Targeting NAMPT for Therapeutic Intervention in Cancer and Inflammation: Structure-Based Drug Design and Biological Screening.NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension.Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin.Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein.Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways.The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity.Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy.Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer.Targeting Metabolism for Cancer Therapy.Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype.Cross resistance to diverse anticancer nicotinamide phosphoribosyltransferase inhibitors induced by FK866 treatment.
P2860
Q26745678-8F6035DC-A21A-4463-B3F3-A13C1291D79BQ26861539-31E4242B-AEB9-4893-BCBB-CD6FC731D226Q28476348-F688CC6D-0145-439D-B7E7-BA9CF6EBA2D2Q28543568-BACFBE2E-87C4-4AA1-BA8A-156D1FD80F52Q28551043-20F61395-8FA3-499C-9768-25E92DF451D6Q30581187-95AF8F23-C150-412D-8C25-DA5BDE711625Q33422176-6D3D0B66-825B-4135-B6C7-C4AD20427F5FQ33591293-EE849493-E9E3-418E-A332-F8ACC3B38BB9Q33827703-6B778700-539B-4354-8967-EF61D8F3938DQ35652041-7A7FB6E9-A914-47E3-A978-433D4F748791Q35727985-99ADD375-91C2-4104-A06A-36B225D32F4BQ36545914-0318F4B2-278C-47FF-BB16-73C8DF2ACE17Q37151029-0E0C07B0-CA75-444B-A8E4-EA9147D74EC3Q37285546-B1CB329A-C171-4A9D-86AF-45018483587AQ37619827-C5CD891D-0A4F-441B-BC73-BF2FBD19CE3AQ37626233-A7315B8E-48A5-42DF-9F73-F4CAA4B8C4CAQ37745422-18604815-4D04-4392-807B-7FCD2D791F8BQ38005192-2881306C-E2F5-42A4-9A6A-9AAD1F98DEEAQ38008839-80CA0709-EAE6-4294-BC9D-11C463B89429Q38405687-60BB66E6-6C24-47AF-BE14-D829A238E426Q38522653-6E15D5C5-2B06-4205-80F9-023673A4B266Q38555243-2FBFEA1D-6369-4087-8597-F558F89DCC76Q38635017-DE5BDBAD-8D44-4C3B-A769-6D76B47CA784Q38703608-C9F4D9CE-1ACB-4EDE-8558-C019786C58A4Q38736710-A1553A03-FC05-40D3-8B84-FDE81EA2997BQ38836229-ADF0B7A6-7144-45F8-A4D5-F3DA31935118Q38889929-F624951B-65EE-4329-8674-A9D4C443990EQ38919749-DB41CB76-E64E-4D54-9D02-65A000F18AFFQ38928592-9031089B-F3F1-410D-A6E0-D3CD1F9F60ACQ38959459-D0D71361-E9D0-4176-92E4-B2DAA62A18E2Q39195646-931C8A7D-6F01-45F4-9774-F36AF38D11B7Q39216584-A06E9484-0CA3-4548-B7BC-B579D8FDE086Q39985659-DB2B0E79-F4FE-4B99-9B5C-871B70BA509DQ42511174-A5052A53-2A18-48C0-8635-7C14A6A01708Q47131402-37B45E60-5E43-4F75-A0A4-C9B184F855BBQ47147548-A7CABF7E-BF43-48BA-B80E-56FB7EFDD1F6Q47646742-6EDE4BC5-9700-4CD2-A32E-96D2959BC136Q48531654-FC0DDC02-DDA0-4583-A910-27F0E3CCDAE8Q51760444-E30C79A3-83FC-41BD-890F-924E2AFC0B62Q53694785-AC0BBC79-A4AA-4AE4-84C4-C2E937CAEADC
P2860
Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Safety and efficacy of NAD dep ...... nd overview of published data.
@ast
Safety and efficacy of NAD dep ...... nd overview of published data.
@en
type
label
Safety and efficacy of NAD dep ...... nd overview of published data.
@ast
Safety and efficacy of NAD dep ...... nd overview of published data.
@en
prefLabel
Safety and efficacy of NAD dep ...... nd overview of published data.
@ast
Safety and efficacy of NAD dep ...... nd overview of published data.
@en
P1476
Safety and efficacy of NAD dep ...... nd overview of published data.
@en
P2093
Ake Berglund
Anne von Heideman
P2888
P304
P356
10.1007/S00280-009-1125-3
P577
2009-09-30T00:00:00Z
P5875
P6179
1043898560